Technology > Biotech & pharma 04 June 2021 Serum Institute of India (SII), the maker of Covishield, the Indian name for Oxford-AstraZeneca's vaccine against the Wuhan virus, has sought indemnity for vaccine failures or side effects on lines demanded by foreign vaccine companies like Pfizer, saying that the government should apply “same rules for all”. Covishield-maker Serum Institute of India (SII) has asked for indemnity from liability for vaccine makers, whether Indian or foreign, after Pfizer and Moderna have sought protection from litigation. The Adar Poonawalla-led SII, which is involved in the trials of three new anti-Coronavirus vaccines, has also sought approval from the Drug Controller General of India (DCGI) for the manufacture of the Russian vaccine Sputnik-V.